Sedation with GPI 15715, a water-soluble prodrug of propofol, using target-controlled infusion in volunteers

Anesthesia and Analgesia

Volumn 100, Issue 3, 2005, Pages 701-706

  Fechner, Jörg ^a   Ihmsen, Harald ^a   Schiessl, Christine ^a   Jeleazcov, Christian ^a   Vornov, James J ^b   Schwilden, Helmut ^a   Schüttler, Jürgen ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b Guilford Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GPI 15715; PHENOL DERIVATIVE; PHOSPHONO 2,6 DIISOPROPYLPHENOL; PRODRUG; PROPOFOL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BISPECTRAL INDEX; BURNING SENSATION; DRUG BLOOD LEVEL; DRUG INFUSION; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; OBSERVER ASSESSMENT OF ALERTNESS SEDATION SCALE; PARESTHESIA; PRIORITY JOURNAL; PROBABILITY; RATING SCALE; SCORING SYSTEM; SEDATION; TARGET CONTROLLED INFUSION; TIME; VOLUNTEER;

ADULT; BLOOD PRESSURE; FEMALE; HEART RATE; HUMANS; HYPNOTICS AND SEDATIVES; MALE; PROPOFOL;

EID: 14544287304     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/01.ANE.0000144772.13372.F4     Document Type: Article

References (28)

1. Kulling D, Rothenbuhler R, Inauen W. Safety of nonanesthetist sedation with propofol for outpatient colonoscopy and esophagogastroduodenoscopy. Endoscopy 2003;35:679-82.
2. Heuss LT, Schnieper P, Drewe J, et al. Safety of propofol for conscious sedation during endoscopic procedures in high-risk patients: a prospective, controlled study. Am J Gastroenterol 2003;98:1751-7.
3. Skoglosa J, Falth-Magnusson K, Stenhammar L. Conscious or deep sedation: a questionnaire regarding the experience of parents, children and staff during small bowel biopsy. Acta Paediatr 2003;92:704-8.
4. Walmsley AJ, McLeod B, Ponte J. The new formulation of I.C.I. 35868 (propofol) as the main agent for minor surgical procedures. Eur J Anaesthesiol 1986;3:19-26.
5. Sklar GE. Propofol and postoperative infections. Ann Pharmacother 1997;31:1521-3.
6. Kimura T, Hasegawa M. Effect of intra-operative propofol administration on post-operative serum lipid concentrations. Masui 2001;50:1009-11.
7. Fechner J, Ihmsen H, Hatterscheid D, et al. Pharmacokinetics and clinical pharmacodynamics of the new propofol prodrug GPI 15715 in volunteers. Anesthesiology 2003;99:303-13.
8. Newson C, Joshi GP, Victory R, White PF. Comparison of propofol administration techniques for sedation during monitored anesthesia care. Anesth Analg 1995;81:486-91.
9. Chernik DA, Gillings D, Laine H, et al. Validity and reliability of the Observer's Assessment of Alertness/Sedation Scale: study with intravenous midazolam. J Clin Psychopharmacol 1990;10: 244-51.
10. Plummer GF. Improved method for the determination of propofol in blood by high-performance liquid chromatography with fluorescence detection. J Chromatogr 1987;421:171-6.
11. Varvel JR, Donoho DL, Shafer SL. Measuring the predictive performance of computer-controlled infusion pumps. J Pharmacokinet Biopharm 1992;20:63-94.
12. Somma J, Donner A, Zomorodi K, et al. Population pharmacodynamics of midazolam administered by target controlled infusion in SICU patients after CABG surgery. Anesthesiology 1998;89:1430-43.
13. Bachmann-Mennenga B, Ohlmer A, Heesen M. Incidence of pain after intravenous injection of a medium-/long-chain triglyceride emulsion of propofol: an observational study in 1375 patients. Arzneimittelforschung 2003;53:621-6.
14. Vasile B, Rasulo F, Candiani A, Latronico N. The pathophysiology of propofol infusion syndrome: a simple name for a complex syndrome. Intensive Care Med 2003;29:1417-25.
15. Egan TD, Kern SE, Johnson KB, Pace NL. The pharmacokinetics and pharmacodynamics of propofol in a modified cyclodextrin formulation (Captisol) versus propofol in a lipid formulation (Diprivan): an electroencephalographic and hemodynamic study in a porcine model. Anesth Analg 2003;97:72-9.
16. Bennett DJ, Anderson A, Buchanan K, et al. Novel water soluble 2,6-dimethoxyphenyl ester derivatives with intravenous anaesthetic activity. Bioorg Med Chem Lett 2003;13:1971-5.
17. Banaszczyk MG, Carlo AT, Millan V, et al. Propofol phosphate, a water-soluble propofol prodrug: in vivo evaluation. Anesth Analg 2002;95:1285-92.
18. Sa Rego MM, Watcha MF, White PF. The changing role of monitored anesthesia care in the ambulatory setting. Anesth Analg 1997;85:1020-36.
19. Casati A, Fanelli G, Casaletti E, et al. Clinical assessment of target-controlled infusion of propofol during monitored anesthesia care. Can J Anaesth 1999;46:235-9.
20. Leslie K, Absalom A, Kenny GN. Closed loop control of sedation for colonoscopy using the Bispectral Index. Anaesthesia 2002;57:693-7.
21. Knibbe CA, Zuideveld KP, DeJongh J, et al. Population pharmacokinetic and pharmacodynamic modeling of propofol for long-term sedation in critically ill patients: a comparison between propofol 6% and propofol 1%. Clin Pharmacol Ther 2002; 72:670-84.
22. 2O sedation. Acta Anaesthesiol Scand 2003;47:951-7.
23. Liu J, Singh H, White PF. Electroencephalographic bispectral index correlates with intraoperative recall and depth of propofol-induced sedation. Anesth Analg 1997;84:185-9.
24. Kearse LAJ, Rosow C, Zaslavsky A, et al. Bispectral analysis of the electroencephalogram predicts conscious processing of information during propofol sedation and hypnosis. Anesthesiology 1998;88:25-34.
25. Fechner J, Albrecht S, Ihmsen H, et al. Predictability and precision of "target-controlled infusion" (TCI) of propofol with the "Disoprifusor TCI" system. Anaesthesist 1998;47:663-8.
26. Vuyk J, Englbers FH, Burm AG, et al. Performance of computer-controlled infusion of propofol: an evaluation of five pharmacokinetic parameter sets. Anesth Analg 1995;81:1275-82.
27. Shinozaki M, Usui Y, Yamaguchi S, et al. Recovery of psychomotor function after propofol sedation is prolonged in the elderly. Can J Anaesth 2002;49:927-31.
28. Luer MS. Fosphenytoin. Neurol Res 1998;20:178-82.